Paolo Tarantino/X
Apr 23, 2025, 10:07
Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn:
“ADCs are rapidly moving to earlier line treatment for breast cancer.
Two positive press releases today (DESTINY-Breast09, ASCENT-04) suggest that we’ll soon start using first-line ADCs for HER2+ and triple negative metastatic breast cancer.
But it’s only the beginning of many further changes in the horizon.
Here’s a recap of key ADC phase 3 trials expected to shape practice in the next future.”
Read this impactful insight about ADCs on OncoDaily:
“Bladder Cancer Treatment: The Game-Changing Role of Antibody-Drug Conjugates (ADCs)”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 23, 2025, 10:05
Apr 23, 2025, 08:35
Apr 23, 2025, 08:18
Apr 23, 2025, 08:09
Apr 23, 2025, 07:49